| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Stromal Tumors | 80 | 2024 | 615 | 10.930 |
Why?
|
| Proto-Oncogene Proteins c-kit | 86 | 2024 | 727 | 8.920 |
Why?
|
| Gastrointestinal Neoplasms | 40 | 2024 | 951 | 4.880 |
Why?
|
| Piperazines | 53 | 2019 | 2525 | 2.670 |
Why?
|
| Pyrimidines | 53 | 2021 | 3016 | 2.550 |
Why?
|
| Translocation, Genetic | 48 | 2018 | 1388 | 2.450 |
Why?
|
| Chromosome Aberrations | 48 | 2023 | 1764 | 2.320 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 24 | 2020 | 367 | 2.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 74 | 2021 | 2506 | 2.000 |
Why?
|
| Leiomyosarcoma | 10 | 2023 | 424 | 1.990 |
Why?
|
| Sarcoma | 23 | 2020 | 1786 | 1.770 |
Why?
|
| Benzamides | 48 | 2016 | 1369 | 1.710 |
Why?
|
| Oncogene Proteins, Fusion | 25 | 2020 | 1596 | 1.630 |
Why?
|
| Drug Resistance, Neoplasm | 35 | 2024 | 5253 | 1.600 |
Why?
|
| Protein Kinase Inhibitors | 34 | 2024 | 5643 | 1.500 |
Why?
|
| Oncogene Proteins | 11 | 2016 | 719 | 1.490 |
Why?
|
| Mesothelioma | 12 | 2023 | 807 | 1.460 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 15 | 2018 | 1613 | 1.360 |
Why?
|
| Sarcoma, Endometrial Stromal | 6 | 2018 | 93 | 1.270 |
Why?
|
| HSP90 Heat-Shock Proteins | 7 | 2019 | 423 | 1.220 |
Why?
|
| Antineoplastic Agents | 54 | 2024 | 13630 | 1.220 |
Why?
|
| Soft Tissue Neoplasms | 22 | 2016 | 1152 | 1.210 |
Why?
|
| Mutation | 63 | 2024 | 29932 | 1.190 |
Why?
|
| Gene Expression Regulation, Neoplastic | 33 | 2021 | 8515 | 1.170 |
Why?
|
| Karyotyping | 58 | 2010 | 1171 | 1.160 |
Why?
|
| DNA-Binding Proteins | 27 | 2023 | 9585 | 1.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 5 | 2016 | 368 | 1.070 |
Why?
|
| Gene Rearrangement | 22 | 2020 | 1122 | 1.010 |
Why?
|
| Uterine Neoplasms | 10 | 2021 | 1439 | 0.970 |
Why?
|
| Cell Proliferation | 32 | 2022 | 10446 | 0.940 |
Why?
|
| Proto-Oncogene Proteins | 12 | 2018 | 4490 | 0.930 |
Why?
|
| Chromosomes, Human, Pair 8 | 15 | 2013 | 452 | 0.910 |
Why?
|
| Dystrophin | 2 | 2015 | 284 | 0.880 |
Why?
|
| Bone Cysts, Aneurysmal | 4 | 2005 | 70 | 0.870 |
Why?
|
| Genes, Tumor Suppressor | 10 | 2023 | 1055 | 0.860 |
Why?
|
| Trisomy | 12 | 2010 | 260 | 0.840 |
Why?
|
| Chromosomes, Human, Pair 17 | 11 | 2012 | 419 | 0.840 |
Why?
|
| Cyclin D1 | 5 | 2019 | 451 | 0.830 |
Why?
|
| Bone Neoplasms | 14 | 2018 | 2532 | 0.820 |
Why?
|
| Cell Line, Tumor | 54 | 2022 | 16939 | 0.820 |
Why?
|
| Genes, p53 | 6 | 2021 | 713 | 0.810 |
Why?
|
| Muscular Dystrophies | 2 | 2015 | 389 | 0.810 |
Why?
|
| Transcription Factors | 34 | 2019 | 12103 | 0.750 |
Why?
|
| Signal Transduction | 51 | 2020 | 23376 | 0.740 |
Why?
|
| Chromosomes, Human, Pair 22 | 11 | 2019 | 346 | 0.740 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2021 | 101 | 0.720 |
Why?
|
| Liposarcoma | 6 | 2015 | 283 | 0.720 |
Why?
|
| Chromosomes, Human, Pair 12 | 10 | 2004 | 430 | 0.680 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2019 | 2448 | 0.680 |
Why?
|
| Phenothiazines | 1 | 2019 | 61 | 0.670 |
Why?
|
| Stromal Cells | 15 | 2004 | 1326 | 0.650 |
Why?
|
| Dermatofibrosarcoma | 6 | 2015 | 48 | 0.650 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2023 | 2919 | 0.650 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 6 | 2017 | 698 | 0.640 |
Why?
|
| Chromosome Deletion | 11 | 2019 | 1387 | 0.630 |
Why?
|
| Osteosarcoma | 4 | 2014 | 897 | 0.620 |
Why?
|
| Leiomyoma | 6 | 2012 | 654 | 0.610 |
Why?
|
| Endometrial Neoplasms | 7 | 2018 | 1357 | 0.610 |
Why?
|
| Protein-Tyrosine Kinases | 12 | 2019 | 2418 | 0.610 |
Why?
|
| Chaperonins | 2 | 2019 | 58 | 0.600 |
Why?
|
| Pleural Neoplasms | 5 | 2018 | 609 | 0.590 |
Why?
|
| 14-3-3 Proteins | 4 | 2013 | 221 | 0.580 |
Why?
|
| Genes, erbB-2 | 4 | 2003 | 162 | 0.580 |
Why?
|
| Immunohistochemistry | 39 | 2021 | 11071 | 0.570 |
Why?
|
| Phosphorylation | 23 | 2019 | 8313 | 0.570 |
Why?
|
| Humans | 331 | 2024 | 760621 | 0.570 |
Why?
|
| Tandem Repeat Sequences | 1 | 2018 | 180 | 0.570 |
Why?
|
| Lipoma | 8 | 2001 | 292 | 0.560 |
Why?
|
| Cell Cycle Proteins | 11 | 2019 | 3446 | 0.560 |
Why?
|
| Gene Duplication | 1 | 2018 | 313 | 0.550 |
Why?
|
| Biological Products | 2 | 2023 | 916 | 0.550 |
Why?
|
| Protein Kinase C | 6 | 2012 | 1199 | 0.550 |
Why?
|
| Chromosomes, Human, Pair 7 | 9 | 2004 | 310 | 0.540 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 119 | 0.540 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2021 | 1115 | 0.530 |
Why?
|
| Pyrroles | 10 | 2020 | 1137 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 6 | 5 | 2003 | 373 | 0.510 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2017 | 317 | 0.510 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2016 | 772 | 0.500 |
Why?
|
| Myofibroblasts | 1 | 2016 | 207 | 0.490 |
Why?
|
| Indoles | 10 | 2016 | 1829 | 0.490 |
Why?
|
| Point Mutation | 3 | 2015 | 1594 | 0.480 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2021 | 1889 | 0.480 |
Why?
|
| Neoplasm Invasiveness | 7 | 2017 | 3618 | 0.480 |
Why?
|
| Stomach Neoplasms | 4 | 2014 | 1423 | 0.470 |
Why?
|
| Chromosomes, Human, Pair 15 | 6 | 2004 | 362 | 0.470 |
Why?
|
| Neoplasm Proteins | 20 | 2016 | 3610 | 0.470 |
Why?
|
| Apoptosis | 27 | 2021 | 9501 | 0.460 |
Why?
|
| Rhabdomyosarcoma | 6 | 2022 | 359 | 0.460 |
Why?
|
| Gene Amplification | 9 | 2013 | 1085 | 0.450 |
Why?
|
| Prostaglandin D2 | 1 | 2014 | 108 | 0.450 |
Why?
|
| Phosphatidylinositol 3-Kinases | 9 | 2022 | 2864 | 0.440 |
Why?
|
| Xenograft Model Antitumor Assays | 17 | 2021 | 3584 | 0.440 |
Why?
|
| Pyridines | 7 | 2019 | 2879 | 0.440 |
Why?
|
| Cytogenetics | 12 | 2016 | 198 | 0.440 |
Why?
|
| Cell Survival | 13 | 2019 | 5797 | 0.440 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2014 | 126 | 0.430 |
Why?
|
| Molecular Sequence Data | 37 | 2014 | 17624 | 0.430 |
Why?
|
| Phenylurea Compounds | 5 | 2019 | 529 | 0.430 |
Why?
|
| Cell Transformation, Neoplastic | 13 | 2020 | 2828 | 0.430 |
Why?
|
| Isoenzymes | 4 | 2012 | 1690 | 0.430 |
Why?
|
| Hamartoma | 5 | 1997 | 235 | 0.420 |
Why?
|
| Kidney Neoplasms | 17 | 2016 | 4312 | 0.420 |
Why?
|
| Carrier Proteins | 5 | 2016 | 4938 | 0.410 |
Why?
|
| Gene Expression Profiling | 17 | 2019 | 9411 | 0.410 |
Why?
|
| Smooth Muscle Tumor | 1 | 2012 | 63 | 0.410 |
Why?
|
| Mediator Complex | 1 | 2012 | 106 | 0.410 |
Why?
|
| Chromosomes, Human, Pair 3 | 4 | 2009 | 315 | 0.400 |
Why?
|
| DNA, Neoplasm | 13 | 2010 | 1745 | 0.400 |
Why?
|
| Tumor Cells, Cultured | 31 | 2021 | 6131 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 18 | 7 | 2010 | 246 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2006 | 1547 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 19 | 5 | 2007 | 347 | 0.390 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 165 | 0.390 |
Why?
|
| Receptor, IGF Type 1 | 5 | 2016 | 380 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 9 | 6 | 2020 | 534 | 0.380 |
Why?
|
| Cell Cycle | 10 | 2019 | 2934 | 0.380 |
Why?
|
| Protein Kinases | 4 | 2012 | 1612 | 0.370 |
Why?
|
| Nuclear Proteins | 12 | 2023 | 5791 | 0.370 |
Why?
|
| Exons | 11 | 2020 | 2388 | 0.370 |
Why?
|
| Receptors, Fibroblast Growth Factor | 3 | 2004 | 192 | 0.370 |
Why?
|
| Oncogenes | 9 | 2013 | 1220 | 0.370 |
Why?
|
| Female | 162 | 2021 | 391270 | 0.370 |
Why?
|
| Chondrosarcoma | 4 | 2016 | 296 | 0.360 |
Why?
|
| Wilms Tumor | 6 | 2000 | 375 | 0.360 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 23 | 2016 | 4573 | 0.360 |
Why?
|
| Disease-Free Survival | 15 | 2018 | 6828 | 0.360 |
Why?
|
| Carcinoma | 6 | 2014 | 2331 | 0.360 |
Why?
|
| Endopeptidases | 2 | 2004 | 772 | 0.360 |
Why?
|
| Fibromatosis, Aggressive | 2 | 2006 | 125 | 0.350 |
Why?
|
| Tropomyosin | 2 | 2020 | 104 | 0.350 |
Why?
|
| Repressor Proteins | 2 | 2018 | 2981 | 0.350 |
Why?
|
| Receptors, Growth Factor | 2 | 2011 | 326 | 0.350 |
Why?
|
| In Situ Hybridization | 8 | 2003 | 1900 | 0.350 |
Why?
|
| Nerve Sheath Neoplasms | 4 | 2010 | 167 | 0.350 |
Why?
|
| DNA Mutational Analysis | 15 | 2018 | 4107 | 0.350 |
Why?
|
| Enzyme Activation | 10 | 2014 | 3602 | 0.340 |
Why?
|
| Dyspepsia | 1 | 2010 | 118 | 0.340 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 3 | 2022 | 100 | 0.340 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2006 | 617 | 0.340 |
Why?
|
| Cadherins | 2 | 2004 | 898 | 0.340 |
Why?
|
| Cytogenetic Analysis | 5 | 2016 | 271 | 0.340 |
Why?
|
| ras Proteins | 2 | 2014 | 1052 | 0.330 |
Why?
|
| Base Sequence | 29 | 2014 | 12446 | 0.330 |
Why?
|
| Male | 147 | 2020 | 359744 | 0.330 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 5 | 2016 | 854 | 0.330 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 11 | 2014 | 3775 | 0.310 |
Why?
|
| Imidazoles | 6 | 2022 | 1180 | 0.310 |
Why?
|
| Chondroblastoma | 2 | 2018 | 48 | 0.310 |
Why?
|
| Loss of Heterozygosity | 2 | 2013 | 659 | 0.310 |
Why?
|
| Lung Neoplasms | 15 | 2021 | 13262 | 0.310 |
Why?
|
| Chromosomes, Human, Pair 13 | 4 | 2004 | 193 | 0.300 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2009 | 263 | 0.300 |
Why?
|
| Cytological Techniques | 3 | 2007 | 218 | 0.300 |
Why?
|
| X Chromosome | 5 | 2002 | 815 | 0.290 |
Why?
|
| Prognosis | 31 | 2020 | 29658 | 0.290 |
Why?
|
| Chromosome Disorders | 7 | 2011 | 499 | 0.290 |
Why?
|
| Receptor, erbB-2 | 5 | 2004 | 2554 | 0.280 |
Why?
|
| Pyridazines | 2 | 2022 | 200 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2021 | 2802 | 0.280 |
Why?
|
| Protein Kinase C-delta | 1 | 2007 | 114 | 0.280 |
Why?
|
| RNA, Small Interfering | 9 | 2018 | 3442 | 0.280 |
Why?
|
| Enzyme Inhibitors | 4 | 2009 | 3726 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 567 | 0.280 |
Why?
|
| Artificial Gene Fusion | 4 | 2004 | 56 | 0.270 |
Why?
|
| Sulfonamides | 6 | 2021 | 1977 | 0.270 |
Why?
|
| TOR Serine-Threonine Kinases | 7 | 2019 | 2058 | 0.270 |
Why?
|
| Sarcoma, Clear Cell | 5 | 2012 | 72 | 0.260 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 2138 | 0.260 |
Why?
|
| Chromosome Banding | 10 | 2016 | 260 | 0.260 |
Why?
|
| Gene Deletion | 8 | 2015 | 2668 | 0.260 |
Why?
|
| Mice, Nude | 10 | 2020 | 3607 | 0.260 |
Why?
|
| Succinate Dehydrogenase | 3 | 2017 | 145 | 0.260 |
Why?
|
| Blotting, Western | 14 | 2016 | 5039 | 0.250 |
Why?
|
| Naphthyridines | 2 | 2024 | 141 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2022 | 556 | 0.250 |
Why?
|
| Doxorubicin | 4 | 2023 | 2209 | 0.250 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 551 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2019 | 9276 | 0.250 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 6 | 2015 | 184 | 0.250 |
Why?
|
| Polymerase Chain Reaction | 12 | 2020 | 6068 | 0.240 |
Why?
|
| Adult | 88 | 2020 | 219994 | 0.240 |
Why?
|
| Adenocarcinoma, Follicular | 3 | 2008 | 325 | 0.240 |
Why?
|
| Mice | 43 | 2023 | 81208 | 0.240 |
Why?
|
| Middle Aged | 81 | 2020 | 220352 | 0.240 |
Why?
|
| Skin Neoplasms | 11 | 2015 | 5799 | 0.240 |
Why?
|
| Gene Expression | 10 | 2016 | 7588 | 0.240 |
Why?
|
| CHO Cells | 4 | 2019 | 1389 | 0.230 |
Why?
|
| Quinazolines | 3 | 2020 | 1363 | 0.230 |
Why?
|
| Animals | 58 | 2023 | 167963 | 0.230 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 4 | 2018 | 256 | 0.230 |
Why?
|
| DNA Repair | 2 | 2023 | 2039 | 0.230 |
Why?
|
| RNA, Neoplasm | 8 | 2010 | 749 | 0.230 |
Why?
|
| Sarcoma, Synovial | 5 | 2002 | 151 | 0.220 |
Why?
|
| Neoplasms | 14 | 2022 | 22072 | 0.220 |
Why?
|
| Genes, myc | 4 | 2003 | 395 | 0.220 |
Why?
|
| Carcinoma, Renal Cell | 10 | 2016 | 3218 | 0.220 |
Why?
|
| Fibrosarcoma | 3 | 2004 | 308 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2022 | 183 | 0.210 |
Why?
|
| Thiazolidinediones | 3 | 2002 | 465 | 0.210 |
Why?
|
| Disease Progression | 14 | 2020 | 13502 | 0.210 |
Why?
|
| Child | 48 | 2020 | 79806 | 0.210 |
Why?
|
| Histones | 6 | 2018 | 2583 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2004 | 342 | 0.210 |
Why?
|
| DNA, Complementary | 7 | 2004 | 1991 | 0.210 |
Why?
|
| Neoplasm Metastasis | 9 | 2020 | 4902 | 0.210 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2023 | 112 | 0.210 |
Why?
|
| Neurofibrosarcoma | 1 | 2022 | 26 | 0.210 |
Why?
|
| Peripheral Nervous System Neoplasms | 2 | 2001 | 133 | 0.210 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2015 | 241 | 0.200 |
Why?
|
| Gonadotropins | 1 | 2003 | 241 | 0.200 |
Why?
|
| Cell Movement | 7 | 2019 | 5206 | 0.200 |
Why?
|
| Cell Nucleus | 8 | 2019 | 2907 | 0.200 |
Why?
|
| Sickle Cell Trait | 2 | 2014 | 85 | 0.200 |
Why?
|
| Gene Dosage | 5 | 2010 | 1218 | 0.200 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 1992 | 32 | 0.200 |
Why?
|
| Poly(A)-Binding Protein I | 1 | 2021 | 15 | 0.190 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 2 | 2021 | 174 | 0.190 |
Why?
|
| Pyrazoles | 3 | 2021 | 1999 | 0.190 |
Why?
|
| Urea | 1 | 2024 | 446 | 0.190 |
Why?
|
| Aged | 64 | 2020 | 169152 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 9 | 2019 | 4713 | 0.190 |
Why?
|
| Zinc Fingers | 3 | 2004 | 568 | 0.190 |
Why?
|
| DNA | 7 | 2023 | 7233 | 0.190 |
Why?
|
| RNA Interference | 7 | 2016 | 2846 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2014 | 285 | 0.190 |
Why?
|
| Granulosa Cell Tumor | 2 | 1992 | 72 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2012 | 276 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 629 | 0.190 |
Why?
|
| Melanoma | 7 | 2018 | 5697 | 0.190 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2002 | 238 | 0.190 |
Why?
|
| Adolescent | 42 | 2018 | 87810 | 0.180 |
Why?
|
| Amino Acid Sequence | 18 | 2021 | 13451 | 0.180 |
Why?
|
| Sulfides | 1 | 2021 | 171 | 0.180 |
Why?
|
| High Mobility Group Proteins | 3 | 2006 | 176 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2016 | 1407 | 0.180 |
Why?
|
| Genes, p16 | 1 | 2021 | 159 | 0.180 |
Why?
|
| Isochromosomes | 2 | 2000 | 16 | 0.180 |
Why?
|
| Biological Evolution | 1 | 2006 | 1074 | 0.180 |
Why?
|
| Breast Neoplasms, Male | 3 | 2003 | 221 | 0.180 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2020 | 34 | 0.170 |
Why?
|
| Receptor, Insulin | 3 | 2017 | 836 | 0.170 |
Why?
|
| Transfection | 9 | 2017 | 5781 | 0.170 |
Why?
|
| Gene Silencing | 4 | 2017 | 1513 | 0.170 |
Why?
|
| Hydroxamic Acids | 2 | 2015 | 482 | 0.170 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2000 | 80 | 0.170 |
Why?
|
| Interstitial Cells of Cajal | 3 | 2014 | 23 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 346 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 14 | 3 | 2017 | 286 | 0.170 |
Why?
|
| Mesoderm | 7 | 2001 | 672 | 0.170 |
Why?
|
| Casein Kinase II | 1 | 2019 | 122 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 3616 | 0.160 |
Why?
|
| Stem Cell Factor | 2 | 2013 | 196 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2020 | 1652 | 0.160 |
Why?
|
| Paired Box Transcription Factors | 2 | 2015 | 207 | 0.160 |
Why?
|
| Cooperative Behavior | 1 | 2006 | 1500 | 0.160 |
Why?
|
| Breast Neoplasms | 13 | 2007 | 21025 | 0.160 |
Why?
|
| Nitrophenols | 2 | 2016 | 169 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 2000 | 313 | 0.160 |
Why?
|
| Mitotic Index | 3 | 2012 | 161 | 0.160 |
Why?
|
| Nephroma, Mesoblastic | 1 | 1998 | 24 | 0.160 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 94 | 0.160 |
Why?
|
| Uveal Neoplasms | 2 | 2012 | 341 | 0.160 |
Why?
|
| Neurofibromin 1 | 3 | 2017 | 190 | 0.160 |
Why?
|
| I-kappa B Proteins | 1 | 2019 | 212 | 0.160 |
Why?
|
| Pathology | 1 | 2002 | 270 | 0.160 |
Why?
|
| Gene Fusion | 3 | 2020 | 354 | 0.160 |
Why?
|
| Child, Preschool | 30 | 2020 | 42063 | 0.160 |
Why?
|
| Infant | 29 | 2020 | 36060 | 0.160 |
Why?
|
| Proline | 1 | 2000 | 457 | 0.160 |
Why?
|
| Cell Differentiation | 9 | 2018 | 11481 | 0.160 |
Why?
|
| Behavior, Animal | 1 | 2006 | 1866 | 0.150 |
Why?
|
| Thyroid Neoplasms | 4 | 2010 | 2332 | 0.150 |
Why?
|
| Inflammation | 2 | 2016 | 10756 | 0.150 |
Why?
|
| Benzoquinones | 2 | 2011 | 198 | 0.150 |
Why?
|
| Cricetulus | 2 | 2019 | 815 | 0.150 |
Why?
|
| Transcription Factor RelA | 1 | 2019 | 251 | 0.150 |
Why?
|
| Alberta | 1 | 2018 | 66 | 0.150 |
Why?
|
| Chromosome Inversion | 1 | 1998 | 120 | 0.150 |
Why?
|
| Trans-Activators | 4 | 2004 | 2860 | 0.150 |
Why?
|
| Testicular Neoplasms | 3 | 2007 | 801 | 0.150 |
Why?
|
| Muscle Neoplasms | 1 | 2019 | 133 | 0.150 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 1998 | 198 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 6 | 2016 | 717 | 0.150 |
Why?
|
| Pituitary Neoplasms | 2 | 2003 | 1313 | 0.140 |
Why?
|
| Models, Biological | 3 | 2007 | 9467 | 0.140 |
Why?
|
| RNA-Binding Protein EWS | 3 | 2006 | 210 | 0.140 |
Why?
|
| Vinculin | 2 | 2014 | 59 | 0.140 |
Why?
|
| Survival Rate | 9 | 2017 | 12808 | 0.140 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2018 | 117 | 0.140 |
Why?
|
| Muscle Proteins | 2 | 2021 | 1152 | 0.140 |
Why?
|
| Lactams, Macrocyclic | 2 | 2011 | 315 | 0.140 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2016 | 12 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 2 | 2019 | 475 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 56 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 4 | 2004 | 1705 | 0.140 |
Why?
|
| Neurilemmoma | 4 | 2014 | 523 | 0.140 |
Why?
|
| Prenatal Diagnosis | 2 | 2016 | 1264 | 0.140 |
Why?
|
| Ubiquitination | 1 | 2021 | 1008 | 0.140 |
Why?
|
| Carcinoma in Situ | 2 | 1999 | 796 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2004 | 3735 | 0.130 |
Why?
|
| Myeloproliferative Disorders | 2 | 2004 | 609 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 11 | 4 | 2003 | 410 | 0.130 |
Why?
|
| Ring Chromosomes | 1 | 1995 | 21 | 0.130 |
Why?
|
| Salvage Therapy | 2 | 2019 | 1268 | 0.130 |
Why?
|
| Threonine | 2 | 2014 | 272 | 0.130 |
Why?
|
| Gene Order | 1 | 2016 | 169 | 0.130 |
Why?
|
| Thiazoles | 4 | 2010 | 1511 | 0.130 |
Why?
|
| Co-Repressor Proteins | 3 | 2012 | 191 | 0.130 |
Why?
|
| Tumor Burden | 7 | 2020 | 1895 | 0.130 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2016 | 197 | 0.130 |
Why?
|
| Karyopherins | 1 | 2016 | 130 | 0.130 |
Why?
|
| Neurofibromin 2 | 1 | 2016 | 270 | 0.130 |
Why?
|
| Adenoma | 4 | 2000 | 2148 | 0.130 |
Why?
|
| Fibromatosis, Abdominal | 1 | 1995 | 21 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 1998 | 385 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2018 | 454 | 0.120 |
Why?
|
| Golgi Apparatus | 1 | 2017 | 404 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2021 | 1728 | 0.120 |
Why?
|
| Chloride Channels | 2 | 2013 | 221 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2014 | 465 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2015 | 15789 | 0.120 |
Why?
|
| Laryngeal Neoplasms | 3 | 2003 | 514 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 6 | 2014 | 5785 | 0.120 |
Why?
|
| DNA Primers | 6 | 2014 | 2819 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 1998 | 635 | 0.120 |
Why?
|
| GTP-Binding Protein alpha Subunits | 2 | 2012 | 102 | 0.120 |
Why?
|
| Gene Library | 2 | 2013 | 1060 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 1999 | 1096 | 0.120 |
Why?
|
| Down-Regulation | 5 | 2016 | 2913 | 0.120 |
Why?
|
| Sequence Deletion | 3 | 2010 | 1493 | 0.120 |
Why?
|
| Biphenyl Compounds | 2 | 2016 | 992 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 5 | 2020 | 2803 | 0.120 |
Why?
|
| Metaphase | 4 | 2001 | 144 | 0.120 |
Why?
|
| Hydrazines | 1 | 2016 | 224 | 0.120 |
Why?
|
| Blotting, Southern | 5 | 2003 | 777 | 0.120 |
Why?
|
| Deoxyglucose | 1 | 2015 | 333 | 0.120 |
Why?
|
| Isoleucine | 1 | 2014 | 110 | 0.120 |
Why?
|
| Ascitic Fluid | 1 | 1994 | 189 | 0.120 |
Why?
|
| Genotype | 10 | 2020 | 12960 | 0.120 |
Why?
|
| Mutation, Missense | 4 | 2010 | 2566 | 0.120 |
Why?
|
| Pulmonary Blastoma | 2 | 2006 | 41 | 0.120 |
Why?
|
| Animals, Genetically Modified | 1 | 2019 | 1553 | 0.120 |
Why?
|
| Endometrial Hyperplasia | 1 | 1995 | 97 | 0.110 |
Why?
|
| Hemangiopericytoma | 1 | 1994 | 71 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-sis | 4 | 2015 | 256 | 0.110 |
Why?
|
| MyoD Protein | 1 | 2014 | 142 | 0.110 |
Why?
|
| STAT1 Transcription Factor | 2 | 2007 | 333 | 0.110 |
Why?
|
| DNA Damage | 1 | 2023 | 2442 | 0.110 |
Why?
|
| Dosage Compensation, Genetic | 1 | 1995 | 207 | 0.110 |
Why?
|
| Genetic Markers | 8 | 2012 | 2608 | 0.110 |
Why?
|
| Membrane Proteins | 3 | 2020 | 7850 | 0.110 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 2210 | 0.110 |
Why?
|
| Retinoblastoma Protein | 3 | 2015 | 670 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2014 | 199 | 0.110 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2013 | 36 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2013 | 28 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 11712 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 6 | 2015 | 6216 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 384 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2004 | 4024 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 1999 | 2299 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2010 | 12914 | 0.110 |
Why?
|
| Staurosporine | 2 | 2004 | 242 | 0.110 |
Why?
|
| DNA Copy Number Variations | 2 | 2013 | 2013 | 0.110 |
Why?
|
| Triterpenes | 1 | 2013 | 81 | 0.100 |
Why?
|
| Carcinoid Tumor | 1 | 2014 | 228 | 0.100 |
Why?
|
| Carcinoma, Papillary | 3 | 2007 | 785 | 0.100 |
Why?
|
| Biopsy | 5 | 2018 | 6771 | 0.100 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 1992 | 44 | 0.100 |
Why?
|
| Chromosomes, Artificial, Yeast | 5 | 2001 | 113 | 0.100 |
Why?
|
| Isoindoles | 1 | 2012 | 36 | 0.100 |
Why?
|
| Osteopontin | 1 | 2014 | 302 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2018 | 17790 | 0.100 |
Why?
|
| Iodide Peroxidase | 1 | 2014 | 294 | 0.100 |
Why?
|
| Muscle Development | 1 | 2014 | 259 | 0.100 |
Why?
|
| Tongue Neoplasms | 1 | 1994 | 183 | 0.100 |
Why?
|
| Mucous Membrane | 2 | 2013 | 657 | 0.100 |
Why?
|
| Chromosome Mapping | 9 | 2004 | 4625 | 0.100 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 444 | 0.100 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2007 | 60 | 0.100 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2012 | 43 | 0.100 |
Why?
|
| Adenocarcinoma | 4 | 1997 | 6315 | 0.100 |
Why?
|
| Liver Neoplasms | 3 | 1999 | 4319 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2018 | 3602 | 0.100 |
Why?
|
| Alternative Splicing | 2 | 2010 | 1091 | 0.100 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 3 | 1997 | 44 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1992 | 377 | 0.100 |
Why?
|
| Mutant Proteins | 2 | 2010 | 492 | 0.100 |
Why?
|
| Sunlight | 1 | 2013 | 337 | 0.100 |
Why?
|
| Cricetinae | 3 | 2004 | 2427 | 0.090 |
Why?
|
| Pleural Effusion | 1 | 1994 | 342 | 0.090 |
Why?
|
| Thyroid Hormones | 1 | 2014 | 403 | 0.090 |
Why?
|
| Europe | 1 | 2018 | 3441 | 0.090 |
Why?
|
| Protein Binding | 6 | 2021 | 9335 | 0.090 |
Why?
|
| Polyps | 1 | 1992 | 197 | 0.090 |
Why?
|
| Brain Neoplasms | 6 | 2015 | 8986 | 0.090 |
Why?
|
| Ploidies | 5 | 1996 | 275 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 2 | 2007 | 877 | 0.090 |
Why?
|
| Glycine | 1 | 2014 | 662 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 1991 | 127 | 0.090 |
Why?
|
| Neurofibromatosis 1 | 4 | 2002 | 560 | 0.090 |
Why?
|
| Triazoles | 1 | 2016 | 904 | 0.090 |
Why?
|
| Pilomatrixoma | 1 | 2010 | 24 | 0.090 |
Why?
|
| Carbonic Anhydrase II | 1 | 2010 | 22 | 0.090 |
Why?
|
| Arginine | 1 | 2014 | 934 | 0.090 |
Why?
|
| Facial Neoplasms | 2 | 2004 | 125 | 0.090 |
Why?
|
| Cell Respiration | 1 | 2010 | 202 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2023 | 678 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6544 | 0.090 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 84 | 0.090 |
Why?
|
| Lentivirus | 1 | 2013 | 506 | 0.090 |
Why?
|
| Ovarian Neoplasms | 4 | 2007 | 4878 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 414 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 5251 | 0.090 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2003 | 286 | 0.090 |
Why?
|
| Aged, 80 and over | 20 | 2018 | 58995 | 0.090 |
Why?
|
| Hair Diseases | 1 | 2010 | 72 | 0.090 |
Why?
|
| Phenanthrolines | 1 | 2009 | 51 | 0.090 |
Why?
|
| Zebrafish | 2 | 2019 | 2997 | 0.080 |
Why?
|
| Tyrosine | 2 | 2007 | 1438 | 0.080 |
Why?
|
| Intestinal Neoplasms | 2 | 2010 | 311 | 0.080 |
Why?
|
| Aniline Compounds | 1 | 2015 | 1069 | 0.080 |
Why?
|
| Esophageal pH Monitoring | 1 | 2010 | 201 | 0.080 |
Why?
|
| Receptor, trkA | 2 | 2020 | 159 | 0.080 |
Why?
|
| Time Factors | 6 | 2018 | 40165 | 0.080 |
Why?
|
| Young Adult | 10 | 2018 | 58741 | 0.080 |
Why?
|
| Ependymoma | 1 | 1992 | 320 | 0.080 |
Why?
|
| Actins | 3 | 2007 | 2049 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 680 | 0.080 |
Why?
|
| Hashimoto Disease | 1 | 2010 | 105 | 0.080 |
Why?
|
| Hypothyroidism | 1 | 2014 | 665 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2019 | 65017 | 0.080 |
Why?
|
| Phenotype | 4 | 2018 | 16546 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 1484 | 0.080 |
Why?
|
| Adamantinoma | 1 | 2008 | 9 | 0.080 |
Why?
|
| Up-Regulation | 4 | 2019 | 4122 | 0.080 |
Why?
|
| Immunoprecipitation | 2 | 2009 | 877 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 1617 | 0.080 |
Why?
|
| Transcription, Genetic | 7 | 2013 | 7593 | 0.080 |
Why?
|
| Codon, Nonsense | 1 | 2009 | 281 | 0.080 |
Why?
|
| Sulfones | 1 | 2011 | 447 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 215 | 0.080 |
Why?
|
| Cell Division | 8 | 2004 | 4463 | 0.080 |
Why?
|
| GPI-Linked Proteins | 1 | 2009 | 468 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 1 | 1994 | 707 | 0.070 |
Why?
|
| Lung Diseases | 2 | 1995 | 1915 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2010 | 431 | 0.070 |
Why?
|
| Struma Ovarii | 1 | 2007 | 11 | 0.070 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2008 | 53 | 0.070 |
Why?
|
| Collagen Type I | 2 | 2015 | 616 | 0.070 |
Why?
|
| Pelvic Neoplasms | 1 | 1989 | 248 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2014 | 2753 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2010 | 535 | 0.070 |
Why?
|
| Desmin | 1 | 2007 | 99 | 0.070 |
Why?
|
| Genes | 2 | 2001 | 1845 | 0.070 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2007 | 20 | 0.070 |
Why?
|
| Dioxoles | 1 | 2007 | 95 | 0.070 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2007 | 81 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2013 | 3682 | 0.070 |
Why?
|
| Mice, SCID | 4 | 2019 | 2627 | 0.070 |
Why?
|
| Game Theory | 1 | 2006 | 23 | 0.070 |
Why?
|
| Activating Transcription Factor 1 | 1 | 2006 | 26 | 0.070 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1986 | 66 | 0.070 |
Why?
|
| Spectral Karyotyping | 1 | 2006 | 12 | 0.070 |
Why?
|
| Cloning, Molecular | 6 | 2003 | 4169 | 0.070 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 1 | 2006 | 41 | 0.070 |
Why?
|
| Muscle, Smooth | 1 | 1990 | 924 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2011 | 1428 | 0.070 |
Why?
|
| Genetic Variation | 2 | 2004 | 6551 | 0.070 |
Why?
|
| Protein Transport | 1 | 2012 | 1964 | 0.070 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1986 | 176 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 1928 | 0.060 |
Why?
|
| Boronic Acids | 1 | 2009 | 914 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 2 | 1995 | 70 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2006 | 1649 | 0.060 |
Why?
|
| Genes, sis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2005 | 112 | 0.060 |
Why?
|
| Leukemia, B-Cell | 1 | 2005 | 84 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4264 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 749 | 0.060 |
Why?
|
| Keratins | 3 | 1997 | 497 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2008 | 484 | 0.060 |
Why?
|
| Genes, Immunoglobulin | 1 | 2005 | 285 | 0.060 |
Why?
|
| Genetic Techniques | 2 | 1999 | 428 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 1628 | 0.060 |
Why?
|
| Sirolimus | 2 | 2014 | 1547 | 0.060 |
Why?
|
| Altruism | 1 | 2006 | 205 | 0.060 |
Why?
|
| Disease Models, Animal | 6 | 2016 | 18137 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2012 | 616 | 0.060 |
Why?
|
| RNA, Messenger | 7 | 2012 | 12766 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2010 | 867 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2016 | 10827 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 12531 | 0.060 |
Why?
|
| Genome, Human | 3 | 2014 | 4417 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2010 | 2053 | 0.060 |
Why?
|
| Paraffin Embedding | 2 | 2003 | 302 | 0.060 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2006 | 259 | 0.060 |
Why?
|
| Cell Line | 8 | 2013 | 15620 | 0.060 |
Why?
|
| Heart Neoplasms | 2 | 2000 | 360 | 0.060 |
Why?
|
| Chromosome Breakage | 2 | 2002 | 159 | 0.060 |
Why?
|
| Pyrazines | 1 | 2009 | 1199 | 0.060 |
Why?
|
| Antibodies | 1 | 2012 | 2421 | 0.060 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2004 | 75 | 0.060 |
Why?
|
| Neoplasm Transplantation | 4 | 2019 | 2014 | 0.060 |
Why?
|
| Adipocytes | 2 | 2009 | 1179 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12159 | 0.060 |
Why?
|
| Medical Oncology | 1 | 1995 | 2313 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2010 | 1207 | 0.060 |
Why?
|
| Phosphotransferases | 1 | 2004 | 303 | 0.060 |
Why?
|
| Blotting, Northern | 4 | 2001 | 1543 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2012 | 2488 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2007 | 618 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2014 | 4373 | 0.050 |
Why?
|
| Clone Cells | 3 | 2007 | 1660 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 816 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 5 | 2018 | 9185 | 0.050 |
Why?
|
| Haploidy | 1 | 2023 | 133 | 0.050 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 1994 | 136 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2003 | 1693 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 3 | 2003 | 115 | 0.050 |
Why?
|
| Cavernous Sinus | 1 | 2004 | 123 | 0.050 |
Why?
|
| Positron-Emission Tomography | 3 | 2009 | 6465 | 0.050 |
Why?
|
| Fluorescence | 3 | 2012 | 751 | 0.050 |
Why?
|
| Seminoma | 1 | 2004 | 134 | 0.050 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 250 | 0.050 |
Why?
|
| Skull Neoplasms | 1 | 2003 | 173 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2000 | 1055 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 653 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 167 | 0.050 |
Why?
|
| Radiation Tolerance | 2 | 1996 | 480 | 0.050 |
Why?
|
| Biopsy, Needle | 5 | 2003 | 1630 | 0.050 |
Why?
|
| Proto-Oncogenes | 1 | 2003 | 320 | 0.050 |
Why?
|
| Parotid Neoplasms | 1 | 2003 | 157 | 0.050 |
Why?
|
| Flow Cytometry | 5 | 2015 | 5870 | 0.050 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2002 | 103 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2007 | 1246 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2005 | 801 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2006 | 869 | 0.050 |
Why?
|
| Urethane | 1 | 2021 | 36 | 0.050 |
Why?
|
| bcl-X Protein | 2 | 2016 | 413 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 1837 | 0.050 |
Why?
|
| Indazoles | 2 | 2014 | 302 | 0.050 |
Why?
|
| Syndrome | 3 | 2010 | 3280 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2010 | 2533 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2006 | 559 | 0.050 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2001 | 43 | 0.050 |
Why?
|
| Dura Mater | 1 | 2003 | 290 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2016 | 1754 | 0.050 |
Why?
|
| Pericytes | 1 | 2004 | 293 | 0.050 |
Why?
|
| Chromosome Painting | 1 | 2001 | 26 | 0.050 |
Why?
|
| Retroelements | 1 | 2022 | 163 | 0.050 |
Why?
|
| Survival Analysis | 6 | 2021 | 10182 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2012 | 143 | 0.050 |
Why?
|
| Collagen | 2 | 2000 | 2636 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2004 | 11345 | 0.050 |
Why?
|
| HeLa Cells | 3 | 2017 | 3105 | 0.050 |
Why?
|
| Lipomatosis, Multiple Symmetrical | 1 | 2000 | 8 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2004 | 1697 | 0.050 |
Why?
|
| beta Catenin | 1 | 2006 | 1043 | 0.050 |
Why?
|
| Phosphoproteins | 3 | 2007 | 2440 | 0.050 |
Why?
|
| Histocytochemistry | 2 | 1998 | 700 | 0.050 |
Why?
|
| Burkitt Lymphoma | 2 | 2003 | 333 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 110 | 0.040 |
Why?
|
| Binding Sites | 3 | 2010 | 6048 | 0.040 |
Why?
|
| Cyclin E | 1 | 2000 | 155 | 0.040 |
Why?
|
| Mitosis | 2 | 2014 | 1191 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2000 | 130 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2004 | 580 | 0.040 |
Why?
|
| RNA-Binding Proteins | 2 | 2007 | 1894 | 0.040 |
Why?
|
| Phenazines | 1 | 2019 | 56 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2004 | 601 | 0.040 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 39261 | 0.040 |
Why?
|
| Aneuploidy | 4 | 2003 | 551 | 0.040 |
Why?
|
| Transcriptional Activation | 3 | 2001 | 1755 | 0.040 |
Why?
|
| Phosphotyrosine | 1 | 2000 | 456 | 0.040 |
Why?
|
| Kinetics | 1 | 2007 | 6377 | 0.040 |
Why?
|
| Testis | 1 | 2003 | 794 | 0.040 |
Why?
|
| Skin Physiological Phenomena | 2 | 1993 | 188 | 0.040 |
Why?
|
| Multigene Family | 3 | 2010 | 1077 | 0.040 |
Why?
|
| Monosomy | 2 | 2004 | 52 | 0.040 |
Why?
|
| Response Elements | 1 | 2000 | 308 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4925 | 0.040 |
Why?
|
| Protein Methyltransferases | 1 | 2018 | 54 | 0.040 |
Why?
|
| Receptor, trkC | 1 | 1998 | 63 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 20509 | 0.040 |
Why?
|
| Neuroblastoma | 2 | 1998 | 1252 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 1110 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 1998 | 69 | 0.040 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 1998 | 12 | 0.040 |
Why?
|
| Triazines | 1 | 2020 | 310 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2001 | 653 | 0.040 |
Why?
|
| Giant Cell Tumors | 1 | 1998 | 90 | 0.040 |
Why?
|
| Lymphocytes | 1 | 1986 | 2611 | 0.040 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1999 | 179 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 6498 | 0.040 |
Why?
|
| Colorimetry | 1 | 1998 | 153 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2011 | 3531 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2007 | 3663 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2000 | 1433 | 0.040 |
Why?
|
| Lymphoma, T-Cell | 1 | 2000 | 305 | 0.040 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2012 | 122 | 0.040 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2016 | 329 | 0.040 |
Why?
|
| Infant, Newborn | 6 | 2004 | 26181 | 0.040 |
Why?
|
| Peritoneal Diseases | 1 | 1998 | 76 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 1998 | 311 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 1993 | 0.040 |
Why?
|
| Kidney | 1 | 1993 | 7064 | 0.040 |
Why?
|
| DNA Probes | 2 | 1995 | 551 | 0.040 |
Why?
|
| K562 Cells | 1 | 2019 | 640 | 0.040 |
Why?
|
| COS Cells | 1 | 2019 | 1129 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2009 | 14660 | 0.040 |
Why?
|
| Diagnosis, Differential | 5 | 2014 | 12965 | 0.040 |
Why?
|
| Genes, ras | 2 | 2007 | 655 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2010 | 225 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2004 | 1304 | 0.040 |
Why?
|
| Fibroma | 1 | 1998 | 190 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 656 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2009 | 178 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2019 | 476 | 0.030 |
Why?
|
| Image Cytometry | 1 | 1997 | 53 | 0.030 |
Why?
|
| HMGA1a Protein | 1 | 1997 | 61 | 0.030 |
Why?
|
| Phagocytosis | 2 | 2013 | 1535 | 0.030 |
Why?
|
| Androgens | 1 | 2004 | 1291 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 783 | 0.030 |
Why?
|
| Retinoids | 1 | 1997 | 98 | 0.030 |
Why?
|
| RNA | 2 | 2004 | 2722 | 0.030 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 1998 | 167 | 0.030 |
Why?
|
| Phthalazines | 1 | 2019 | 383 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2013 | 10181 | 0.030 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1998 | 687 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1996 | 38 | 0.030 |
Why?
|
| Lung | 3 | 1997 | 9994 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 935 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1996 | 58 | 0.030 |
Why?
|
| Heterozygote | 4 | 2013 | 2798 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2012 | 4642 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2008 | 1895 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1997 | 224 | 0.030 |
Why?
|
| Culture Techniques | 2 | 1997 | 530 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 1998 | 372 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 724 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1996 | 125 | 0.030 |
Why?
|
| Nucleic Acid Precursors | 1 | 2015 | 15 | 0.030 |
Why?
|
| Glioblastoma | 2 | 2009 | 3484 | 0.030 |
Why?
|
| HLA-DQ Antigens | 2 | 1993 | 211 | 0.030 |
Why?
|
| Introns | 3 | 2004 | 978 | 0.030 |
Why?
|
| Diploidy | 2 | 1998 | 132 | 0.030 |
Why?
|
| Mucin-1 | 2 | 1997 | 539 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 1986 | 5496 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 1998 | 733 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2010 | 1895 | 0.030 |
Why?
|
| Sex Chromosome Aberrations | 1 | 1995 | 116 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 20080 | 0.030 |
Why?
|
| Freezing | 1 | 1995 | 306 | 0.030 |
Why?
|
| Centromere | 1 | 1995 | 213 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2000 | 3084 | 0.030 |
Why?
|
| Cisplatin | 2 | 2016 | 1644 | 0.030 |
Why?
|
| Meningeal Neoplasms | 1 | 2004 | 1249 | 0.030 |
Why?
|
| Chromosomes, Human, 13-15 | 2 | 2004 | 49 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2004 | 15289 | 0.030 |
Why?
|
| Asbestos, Amosite | 1 | 1994 | 1 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2001 | 3615 | 0.030 |
Why?
|
| Remission Induction | 3 | 2005 | 2392 | 0.030 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 1994 | 42 | 0.030 |
Why?
|
| Genes, Wilms Tumor | 1 | 1994 | 92 | 0.030 |
Why?
|
| Butadienes | 1 | 2014 | 107 | 0.030 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 1994 | 50 | 0.030 |
Why?
|
| Chromones | 1 | 2014 | 149 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 4166 | 0.030 |
Why?
|
| United States | 2 | 2018 | 72461 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2002 | 1677 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 2105 | 0.030 |
Why?
|
| raf Kinases | 1 | 2014 | 118 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 12626 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2009 | 2471 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2010 | 3790 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2014 | 122 | 0.030 |
Why?
|
| Niflumic Acid | 1 | 2013 | 10 | 0.030 |
Why?
|
| Nitrobenzoates | 1 | 2013 | 16 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1997 | 563 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1995 | 341 | 0.030 |
Why?
|
| DNA Replication | 1 | 2000 | 1412 | 0.030 |
Why?
|
| Maleimides | 1 | 2013 | 113 | 0.030 |
Why?
|
| Mosaicism | 2 | 1998 | 466 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2010 | 54303 | 0.030 |
Why?
|
| SOXD Transcription Factors | 1 | 2013 | 44 | 0.030 |
Why?
|
| Neoplasm Staging | 4 | 2012 | 11152 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2014 | 548 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 861 | 0.030 |
Why?
|
| Schwann Cells | 1 | 1994 | 196 | 0.030 |
Why?
|
| Proteins | 3 | 2000 | 6029 | 0.030 |
Why?
|
| Aminophenols | 1 | 2013 | 86 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2007 | 557 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 4899 | 0.030 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2012 | 15 | 0.030 |
Why?
|
| Hepatic Stellate Cells | 1 | 2013 | 119 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2021 | 14372 | 0.030 |
Why?
|
| Chromosome Walking | 1 | 2012 | 25 | 0.030 |
Why?
|
| Cysts | 1 | 1998 | 683 | 0.030 |
Why?
|
| Methods | 1 | 1992 | 1074 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2002 | 2049 | 0.030 |
Why?
|
| Sex Factors | 2 | 2015 | 10547 | 0.030 |
Why?
|
| Rhabdoid Tumor | 1 | 1994 | 210 | 0.030 |
Why?
|
| Fibroblasts | 4 | 1997 | 4090 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 1544 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 1994 | 442 | 0.030 |
Why?
|
| Microscopy, Electron | 3 | 2001 | 2558 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2012 | 93 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2016 | 624 | 0.020 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1992 | 101 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 1139 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2012 | 111 | 0.020 |
Why?
|
| Glycosylation | 1 | 2015 | 1096 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2014 | 5434 | 0.020 |
Why?
|
| Genome | 1 | 2000 | 1739 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 858 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 410 | 0.020 |
Why?
|
| Purines | 1 | 2015 | 605 | 0.020 |
Why?
|
| Sarcoma, Experimental | 1 | 1991 | 117 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2012 | 311 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 1992 | 451 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1997 | 1088 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 358 | 0.020 |
Why?
|
| Aminopyridines | 1 | 2015 | 564 | 0.020 |
Why?
|
| Adipose Tissue | 2 | 2000 | 3301 | 0.020 |
Why?
|
| Electron Transport Complex II | 1 | 2010 | 53 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 319 | 0.020 |
Why?
|
| Reference Values | 2 | 1995 | 4925 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 530 | 0.020 |
Why?
|
| Morpholines | 1 | 2014 | 583 | 0.020 |
Why?
|
| Alleles | 3 | 2001 | 6898 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 551 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 1135 | 0.020 |
Why?
|
| Methylation | 1 | 2013 | 1082 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 532 | 0.020 |
Why?
|
| Ovary | 1 | 1995 | 958 | 0.020 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 1403 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 1741 | 0.020 |
Why?
|
| Kidney Medulla | 1 | 2010 | 169 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 1763 | 0.020 |
Why?
|
| Vimentin | 1 | 1991 | 255 | 0.020 |
Why?
|
| Erythropoietin | 1 | 1994 | 720 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2014 | 1234 | 0.020 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 1990 | 64 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1993 | 928 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2012 | 731 | 0.020 |
Why?
|
| Germ-Line Mutation | 2 | 2010 | 1841 | 0.020 |
Why?
|
| Cells, Cultured | 4 | 2013 | 18957 | 0.020 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 518 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2017 | 4000 | 0.020 |
Why?
|
| Imides | 1 | 2009 | 15 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 4407 | 0.020 |
Why?
|
| CpG Islands | 1 | 2014 | 1221 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2015 | 858 | 0.020 |
Why?
|
| Genes, jun | 1 | 2009 | 68 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 1 | 2009 | 20 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2009 | 129 | 0.020 |
Why?
|
| Neurofibroma | 1 | 2010 | 94 | 0.020 |
Why?
|
| Mucins | 1 | 1992 | 568 | 0.020 |
Why?
|
| Hemangioma | 1 | 1994 | 728 | 0.020 |
Why?
|
| Philadelphia Chromosome | 1 | 1989 | 117 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 22023 | 0.020 |
Why?
|
| Paraganglioma | 1 | 2010 | 142 | 0.020 |
Why?
|
| Retrospective Studies | 7 | 2020 | 80372 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 642 | 0.020 |
Why?
|
| Nitriles | 1 | 2014 | 956 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 2717 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 670 | 0.020 |
Why?
|
| Risk Factors | 3 | 2012 | 74359 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 566 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 759 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1999 | 3765 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2014 | 1016 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2009 | 198 | 0.020 |
Why?
|
| Precipitin Tests | 2 | 2004 | 814 | 0.020 |
Why?
|
| Homeostasis | 1 | 2019 | 3306 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2007 | 44 | 0.020 |
Why?
|
| 5' Flanking Region | 1 | 2007 | 31 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2000 | 3387 | 0.020 |
Why?
|
| Codon | 1 | 2009 | 602 | 0.020 |
Why?
|
| Glioma | 2 | 2009 | 3420 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 631 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 4742 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2007 | 148 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2010 | 943 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 197 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 614 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2013 | 965 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2009 | 2186 | 0.020 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 2006 | 25 | 0.020 |
Why?
|
| Mast Cells | 1 | 1994 | 1390 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1986 | 168 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 1062 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1998 | 3486 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1994 | 1056 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 1986 | 115 | 0.020 |
Why?
|
| Genomics | 2 | 2014 | 5794 | 0.020 |
Why?
|
| Piperidines | 1 | 2015 | 1650 | 0.020 |
Why?
|
| SOXE Transcription Factors | 1 | 2006 | 73 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2006 | 330 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 1997 | 4291 | 0.020 |
Why?
|
| Muscles | 1 | 1991 | 1581 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2007 | 268 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2010 | 698 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 1737 | 0.020 |
Why?
|
| Albumins | 1 | 2008 | 575 | 0.020 |
Why?
|
| Fatal Outcome | 2 | 2001 | 1832 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 718 | 0.020 |
Why?
|
| Sequence Alignment | 2 | 2000 | 2176 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1992 | 2693 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 2651 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 2004 | 192 | 0.010 |
Why?
|
| Diaphragm | 2 | 1998 | 351 | 0.010 |
Why?
|
| Chromosomes, Human, 19-20 | 1 | 2003 | 11 | 0.010 |
Why?
|
| Dysgerminoma | 1 | 2004 | 66 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 1974 | 0.010 |
Why?
|
| Osteoclasts | 1 | 2008 | 711 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2012 | 1913 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2008 | 1600 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2010 | 1356 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2006 | 41335 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 697 | 0.010 |
Why?
|
| Skin | 2 | 1993 | 4466 | 0.010 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2003 | 96 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 1994 | 1809 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2009 | 2648 | 0.010 |
Why?
|
| Germinoma | 1 | 2004 | 132 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1986 | 695 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3094 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 2 | 2001 | 3800 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2003 | 103 | 0.010 |
Why?
|
| Ligands | 2 | 2002 | 3276 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2010 | 2698 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2007 | 36290 | 0.010 |
Why?
|
| Models, Genetic | 2 | 2004 | 3442 | 0.010 |
Why?
|
| Chromatin | 2 | 2007 | 2938 | 0.010 |
Why?
|
| Melanocytes | 1 | 2006 | 512 | 0.010 |
Why?
|
| Laminin | 1 | 2004 | 405 | 0.010 |
Why?
|
| Radiography | 2 | 2007 | 6965 | 0.010 |
Why?
|
| Osteoblasts | 1 | 2008 | 1142 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2002 | 154 | 0.010 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2002 | 199 | 0.010 |
Why?
|
| Drug Discovery | 1 | 2010 | 1057 | 0.010 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2004 | 491 | 0.010 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2001 | 57 | 0.010 |
Why?
|
| Bone Marrow | 2 | 2006 | 2912 | 0.010 |
Why?
|
| Interleukin-3 | 1 | 2003 | 425 | 0.010 |
Why?
|
| Epiglottis | 1 | 2001 | 81 | 0.010 |
Why?
|
| Dactinomycin | 1 | 2001 | 304 | 0.010 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2001 | 57 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 3758 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 2007 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2825 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2005 | 1007 | 0.010 |
Why?
|
| Activin Receptors | 1 | 2000 | 40 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 590 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 9530 | 0.010 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2003 | 301 | 0.010 |
Why?
|
| Age Factors | 1 | 1997 | 18416 | 0.010 |
Why?
|
| Contig Mapping | 1 | 1999 | 54 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 10344 | 0.010 |
Why?
|
| Leg | 1 | 2005 | 1090 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2000 | 3804 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 839 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 8950 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 1788 | 0.010 |
Why?
|
| Color | 1 | 2001 | 298 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2001 | 388 | 0.010 |
Why?
|
| Inhibins | 1 | 2000 | 209 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1997 | 5351 | 0.010 |
Why?
|
| S Phase | 1 | 2000 | 422 | 0.010 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2003 | 495 | 0.010 |
Why?
|
| Follistatin | 1 | 2000 | 137 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 786 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 421 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 1672 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 1244 | 0.010 |
Why?
|
| Vincristine | 1 | 2001 | 1039 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2007 | 1885 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 428 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 1343 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2000 | 454 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2001 | 649 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 2414 | 0.010 |
Why?
|
| Activins | 1 | 2000 | 211 | 0.010 |
Why?
|
| Dibenzoxazepines | 1 | 1978 | 8 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2009 | 2821 | 0.010 |
Why?
|
| Gene Expression Regulation | 3 | 2003 | 11903 | 0.010 |
Why?
|
| Luciferases | 1 | 2000 | 716 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2013 | 9287 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1993 | 3455 | 0.010 |
Why?
|
| Myoglobin | 1 | 1998 | 159 | 0.010 |
Why?
|
| Macrophages | 1 | 2013 | 5745 | 0.010 |
Why?
|
| Skin Absorption | 1 | 1978 | 94 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22053 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 768 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 830 | 0.010 |
Why?
|
| Pedigree | 1 | 2005 | 4578 | 0.010 |
Why?
|
| Proteomics | 1 | 2010 | 3817 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 1997 | 91 | 0.010 |
Why?
|
| Chromosomes | 1 | 2000 | 575 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 2893 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 3847 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 1997 | 364 | 0.010 |
Why?
|
| Solvents | 1 | 1978 | 292 | 0.010 |
Why?
|
| Caspases | 1 | 1999 | 878 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1997 | 228 | 0.010 |
Why?
|
| Myosins | 1 | 1998 | 405 | 0.010 |
Why?
|
| Permeability | 1 | 1978 | 719 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 6218 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 2221 | 0.010 |
Why?
|
| Recurrence | 1 | 2008 | 8482 | 0.010 |
Why?
|
| Neutrophils | 1 | 2008 | 3767 | 0.010 |
Why?
|
| HMGA2 Protein | 1 | 1995 | 102 | 0.010 |
Why?
|
| Liver | 1 | 1991 | 7509 | 0.010 |
Why?
|
| Intermediate Filaments | 1 | 1995 | 172 | 0.010 |
Why?
|
| Breast | 1 | 2003 | 1963 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 3529 | 0.010 |
Why?
|
| Asbestos, Amphibole | 1 | 1994 | 7 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1997 | 911 | 0.010 |
Why?
|
| Polycythemia | 1 | 1994 | 125 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 526 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1994 | 418 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2000 | 1375 | 0.010 |
Why?
|
| Paraneoplastic Syndromes | 1 | 1994 | 155 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1992 | 422 | 0.010 |
Why?
|
| Genes, Neurofibromatosis 1 | 1 | 1992 | 74 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1994 | 522 | 0.010 |
Why?
|
| Pleura | 1 | 1994 | 244 | 0.010 |
Why?
|
| Artifacts | 1 | 2001 | 1898 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2000 | 2208 | 0.010 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1992 | 93 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1997 | 1368 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1997 | 2381 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1992 | 316 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1992 | 763 | 0.010 |
Why?
|
| Rabbits | 1 | 1978 | 4773 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1993 | 630 | 0.010 |
Why?
|
| Temperature | 1 | 1978 | 2221 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 778 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2873 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 6538 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 8552 | 0.010 |
Why?
|
| Spleen | 1 | 1997 | 2298 | 0.010 |
Why?
|
| Calcinosis | 1 | 1999 | 1476 | 0.010 |
Why?
|
| Epithelium | 1 | 1995 | 1605 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1997 | 1765 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1995 | 1204 | 0.010 |
Why?
|
| Rats | 2 | 1994 | 23711 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 29749 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1994 | 707 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 13981 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1993 | 1446 | 0.000 |
Why?
|
| Risk | 1 | 2000 | 9631 | 0.000 |
Why?
|
| Lipid Metabolism | 1 | 1997 | 1902 | 0.000 |
Why?
|
| Drosophila melanogaster | 1 | 1997 | 1710 | 0.000 |
Why?
|
| Placenta | 1 | 1997 | 1702 | 0.000 |
Why?
|
| Radiation Dosage | 1 | 1996 | 1958 | 0.000 |
Why?
|
| Transforming Growth Factor beta | 1 | 1995 | 1959 | 0.000 |
Why?
|
| Transplantation, Heterologous | 1 | 1994 | 2379 | 0.000 |
Why?
|
| Linear Models | 1 | 1996 | 5877 | 0.000 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1997 | 3604 | 0.000 |
Why?
|
| Disease Susceptibility | 1 | 1992 | 1791 | 0.000 |
Why?
|
| Research Design | 1 | 2001 | 6180 | 0.000 |
Why?
|
| Incidence | 1 | 2003 | 21392 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 8158 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2003 | 24123 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1993 | 3047 | 0.000 |
Why?
|
| Brain | 1 | 1997 | 26951 | 0.000 |
Why?
|